M
Marybeth A. Pysz
Researcher at Stanford University
Publications - 43
Citations - 2678
Marybeth A. Pysz is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Cyclin D1. The author has an hindex of 25, co-authored 40 publications receiving 2367 citations. Previous affiliations of Marybeth A. Pysz include North Carolina State University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Molecular Imaging: Current Status and Emerging Strategies
TL;DR: Current preclinical findings and advances in instrumentation suggest that these molecular imaging methods have numerous potential clinical applications and will be translated into clinical use in the near future.
Journal ArticleDOI
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura Saunders,Alexander J. Bankovich,Wade C. Anderson,Monette Aujay,Sheila Bheddah,KristenAnn Black,Desai Radhika Chetan,Paul Anthony Escarpe,Johannes Hampl,Amy Laysang,David R. Liu,Javier Lopez-Molina,Milly Milton,Albert Park,Marybeth A. Pysz,Hui Shao,Brian Slingerland,Torgov Michael,Samuel A. Williams,Orit Foord,Howard Philip Wilson,Jacek Jassem,Andrzej Badzio,Piotr Czapiewski,David H. Harpole,Afshin Dowlati,Pierre P. Massion,William D. Travis,M. Catherine Pietanza,M. Catherine Pietanza,John T. Poirier,John T. Poirier,Charles M. Rudin,Robert A. Stull,Scott J. Dylla +34 more
TL;DR: The authors targeted DLL3 with an antibody conjugated to a cytotoxic drug, which proved to be much more effective than standard chemotherapy for treating patient-derived tumor xenografts and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.
Journal ArticleDOI
Antiangiogenic Cancer Therapy: Monitoring with Molecular US and a Clinically Translatable Contrast Agent (BR55)
Marybeth A. Pysz,Kira Foygel,Jarrett Rosenberg,Sanjiv S. Gambhir,Michel Schneider,Jürgen K. Willmann +5 more
TL;DR: Human MB(KDR) allow in vivo imaging and longitudinal monitoring of VEGFR2 expression in human colon cancer xenografts and in vivo receptor blocking with anti-VEGFR2 antibody is tested.
Journal ArticleDOI
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
Marc Damelin,Alexander J. Bankovich,Jeffrey Bernstein,Justin Lucas,Liang Chen,Samuel A. Williams,Albert Park,Jorge Aguilar,Elana Ernstoff,Manoj Charati,Russell Dushin,Monette Aujay,Christina R. Lee,Hanna Ramoth,Milly Milton,Johannes Hampl,Sasha Lazetic,Virginia Pulito,Edward Rosfjord,Yongliang Sun,Lindsay King,Frank Barletta,Alison Betts,Magali Guffroy,Hadi Falahatpisheh,Christopher J. O’Donnell,Robert A. Stull,Marybeth A. Pysz,Paul Anthony Escarpe,David R. Liu,Orit Foord,Hans-Peter Gerber,Puja Sapra,Scott J. Dylla +33 more
TL;DR: The authors demonstrated the effectiveness of this therapy in mouse models of several tumor types and confirmed that it reduces tumor-initiating cells and outperforms standard chemotherapy, and also had some unexpected benefits, reducing tumor angiogenesis and promoting antitumor immunity.
Journal ArticleDOI
Growth of Hyperthermophilic Archaeon Pyrococcus furiosus on Chitin Involves Two Family 18 Chitinases
TL;DR: Two open reading frames (chiA and chiB) were identified in the genome of P. furiosus, which encodes chitinases with sequence similarity to proteins from the glycosyl hydrolase family 18 in less-thermophilic organisms, indicating that these two enzymes work together to recruit chit in-based substrates for P.furiosus growth.